Health News

Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a ‘common mechanism’ could lead to new treatments for Leprosy, Crohn’s Disease, AIDS and some forms of cancer..

Read more

Filed under: Pharmacy News
Tags: AIDS, cancer, Drug, Pharmacy

Related posts

• Research marks new direction to treat Pneumocystis, inflammatory diseases (0)
  A drug to treat inflammation plays a surprising role reducing the level of infection caused by an opportunistic bug that is deadly for AIDS and cancer patients and others with weakened immune systems. Read more [tags] Pharmacy News [/tags]
  
  
• Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma (0)
  BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency (AFSSaPS) to enter first Phase I clinical trial for Fentanyl Lauriad®. Read more [tags] Pharmacy News [/tags]
  
  
• Gonorrhea medication may help fight cancer (0)
  Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. The newest surprise discovered by researchers at the Johns Hopkins University School of Medicine is a gonorrhea medication that might help battle cancer. Read more [tags] Pharmacy News [/tags]
  
  
• FDA drafts new rules for testing, approving drug cocktails; Public-private partnership for TB treatment development launched (0)
  The FDA is drafting new guidelines for testing and approving multidrug cocktails for life-threatening diseases, the Wall Street Journal reports. "Many diseases, such as AIDS, tuberculosis and cancer, require multidrug combinations. Such drug cocktails can prevent the development of drug resistance, because the microbe or cancer cell needs to undergo more mutations to escape several [...]
  
  
• BioAlliance Pharma’s new drug application for oropharyngeal candidiasis treatment accepted by the FDA (0)
  BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via [...]